Home R&D Page 4

R&D

Alnylam aligns with FDA for accelerated development of lumasiran in the...

New intermediate data in mycosis fungoides from a phase 1 study...

Virtual trial

Industry embraces the virtual trial platforms

A Global Commission to accelerate diagnosis in rare diseases

Phase 2a clinical study on Molgradex for the treatment of NTM...

A new kilolab plant to develop and manufacture a wider range...

New phase 2 data for upadacitinib in 52-week Crohn’s disease

Phase 2a clinical study on Molgradex for the treatment of NTM...

Encouraging results for bispecific antibody in macular diabetic edema

First bispecific monoclonal antibody approved to treat hemophilia A with inhibitors

1...345...17Page 4 of 17
© © 2025 Tecniche Nuove Spa - All rights reserved. Registered office: Via Eritrea 21 - 20157 Milan. Share capital: 5,000,000 Euro fully paid up. Tax code, VAT number and registration with the Milan Register of Companies: 00753480151